Abstract
In the article by Heidenreich et al, “2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures,” which published ahead of print on June 27, 2016, and appeared in the July 2016 issue of the journal ( Circ Cardiovasc Qual Outcomes. 2016;9:443–488. DOI: 10.1161/HCQ.0000000000000018), several corrections were needed. 1. In response to new data that resulted in changes in the US Food and Drug Administration labeling regarding the use of one of the Factor Xa inhibitors in patients with end-stage kidney disease or on dialysis,1 the Task Force on Performance Measures has removed 2 quality measures. They appeared in Appendix A and are: They are shown below. 2. On page 444, the Table of Contents entries for “QM-6: Atrial Fibrillation: …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
